Talquetamab for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, it does mention that certain treatments, like monoclonal antibody therapy and cytotoxic therapy, should not have been received within a specific time frame before enrollment. It's best to discuss your current medications with the trial team to get a clear answer.
Is Talquetamab safe for humans?
How is the drug talquetamab different from other treatments for multiple myeloma?
Talquetamab is unique because it is a first-in-class bispecific antibody that targets a specific protein (GPRC5D) found on cancerous plasma cells and recruits T cells to attack them. This approach is different from other treatments that target more common proteins like CD38, and it has shown significant anticancer effects in patients with relapsed or refractory multiple myeloma.12356
What data supports the effectiveness of the drug Talquetamab for treating multiple myeloma?
Who Is on the Research Team?
Sham Mailankody, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with multiple myeloma who've had BCMA CAR T-cell therapy. They must be in good health, not planning to have children soon, and able to follow the study plan. People can't join if they've had certain other treatments recently, are pregnant or breastfeeding, have serious infections or illnesses that could affect participation, or require high doses of steroids.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive subcutaneous Talquetamab after BCMA CAR T-cell therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Talquetamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Janssen Pharmaceuticals
Industry Sponsor
Joaquin Duato
Janssen Pharmaceuticals
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Pharmaceuticals
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University